University of Baltimore, School of Public Affairs, Health Systems Managment, 1304 St. Paul St., Room 204, Baltimore, MD 21202, USA.
Expert Rev Pharmacoecon Outcomes Res. 2001 Dec;1(2):133-44. doi: 10.1586/14737167.1.2.133.
Governments, organizations and industry routinely make decisions regarding the value of pharmaceuticals. The perspectives, techniques, decision constraints and available information differ across these decision-makers and sometimes within categories. Although pharmacoeconomics is consistent with the international trend toward evidence-based decisions in medicine and could benefit all of these decision-makers, the potential impact of these studies has been largely unrealized. Why is it that a field to which so much research funding has been devoted, has produced so little of clear use to major decision-makers? Would inflexible organizational barriers surrounding narrowly defined performance incentives and line item budget accountability limit the usefulness of even impeccably performed pharmacoeconomic studies? Or, are methodological and logistical considerations impeding the usefulness of pharmacoeconomics?
政府、组织和行业通常会就药品的价值做出决策。这些决策者之间，甚至在同一类别内，其观点、技术、决策限制和可用信息都存在差异。尽管药物经济学符合医学循证决策的国际趋势，可能使所有这些决策者受益，但这些研究的潜在影响在很大程度上尚未实现。为什么一个投入了如此多研究资金的领域，却没有产生对主要决策者有明显用途的研究成果呢？是否僵化的组织障碍，例如狭隘的绩效激励和逐项预算问责制，限制了即使是完美执行的药物经济学研究的实用性？或者，是方法学和后勤方面的考虑因素阻碍了药物经济学的实用性？
